Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2017, Article ID 4517834, 5 pages
https://doi.org/10.1155/2017/4517834
Review Article

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA

1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
2Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
3Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA
4Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
5Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
6Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

Correspondence should be addressed to Bob T. Li; gro.ccksm@1bil

Received 6 January 2017; Accepted 28 February 2017; Published 14 March 2017

Academic Editor: Subodh Kumar

Copyright © 2017 Michael Offin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Kris, B. E. Johnson, L. D. Berry et al., “Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs,” JAMA, vol. 311, no. 19, pp. 1998–2006, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Greaves and C. C. Maley, “Clonal evolution in cancer,” Nature, vol. 481, no. 7381, pp. 306–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Bambury, D. G. Power, and S. O'Reilly, “Intratumor heterogeneity and branched evolution,” The New England Journal of Medicine, vol. 366, no. 22, p. 2132, 2012. View at Publisher · View at Google Scholar
  6. E. I. Pentsova, R. H. Shah, J. Tang et al., “Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid,” Journal of Clinical Oncology, vol. 34, no. 20, pp. 2404–2415, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. D. A. Haber, N. S. Gray, and J. Baselga, “The evolving war on cancer,” Cell, vol. 145, no. 1, pp. 19–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Thompson, S. S. Yee, A. B. Troxel et al., “Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA,” Clinical Cancer Research, vol. 22, no. 23, pp. 5772–5782, 2016. View at Publisher · View at Google Scholar
  9. L. De Mattos-Arruda, R. Mayor, C. K. Y. Ng et al., “Cerebrospinal fluid-derived circulating tumor DNA better represents the genomic alterations of brain tumors than plasma,” Nature Communications, vol. 6, article 8839, 2015. View at Google Scholar
  10. S. Chen, J. Zhao, L. Cui, and Y. Liu, “Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs,” Clinical and Translational Oncology, vol. 19, no. 3, pp. 332–340, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, and B. Vogelstein, “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8817–8822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Diehl, M. Li, Y. He, K. W. Kinzler, B. Vogelstein, and D. Dressman, “BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions,” Nature Methods, vol. 3, no. 7, pp. 551–559, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. R. Oxnard, C. P. Paweletz, Y. Kuang et al., “Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA,” Clinical Cancer Research, vol. 20, no. 6, pp. 1698–1705, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Serratì, S. De Summa, B. Pilato et al., “Next-generation sequencing: advances and applications in cancer diagnosis,” OncoTargets and Therapy, vol. Volume 9, pp. 7355–7365, 2016. View at Publisher · View at Google Scholar
  15. D. Sie, P. J. F. Snijders, G. A. Meijer et al., “Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology,” Cellular Oncology, vol. 37, no. 5, pp. 353–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Newman, S. V. Bratman, J. To et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage,” Nature Medicine, vol. 20, no. 5, pp. 548–554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Newman, A. F. Lovejoy, D. M. Klass et al., “Integrated digital error suppression for improved detection of circulating tumor DNA,” Nature Biotechnology, vol. 34, no. 5, pp. 547–555, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. L. V. Sequist, B. A. Waltman, D. Dias-Santagata et al., “Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors,” Science Translational Medicine, vol. 3, no. 75, p. 75ra26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. A. Yu, M. E. Arcila, N. Rekhtman et al., “Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers,” Clinical Cancer Research, vol. 19, no. 8, pp. 2240–2247, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Ohashi, L. V. Sequist, M. E. Arcila et al., “Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 31, pp. E2127–E2133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. B. S. Sorensen, L. Wu, W. Wei et al., “Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib,” Cancer, vol. 120, no. 24, pp. 3896–3901, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Taniguchi, J. Uchida, K. Nishino et al., “Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas,” Clinical Cancer Research, vol. 17, no. 24, pp. 7808–7815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. Jänne, J. Chih-Hsin Yang, D.-W. Kim et al., “AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 18, pp. 1689–1699, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. K. S. Thress, C. P. Paweletz, E. Felip et al., “Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M,” Nature Medicine, vol. 21, no. 6, pp. 560–562, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. J. Chabon, A. D. Simmons, A. F. Lovejoy et al., “Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients,” Nature Communications, vol. 7, Article ID 11815, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. T. S. Mok, Y. Wu, M. Ahn et al., “Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer,” New England Journal of Medicine, vol. 376, no. 7, pp. 629–640, 2017. View at Publisher · View at Google Scholar
  27. Y. L. Wu, S. Jenkins, S. Ramalingam et al., “MA08.03 osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis,” Journal of Thoracic Oncology, vol. 12, no. 1, p. S386, 2017. View at Publisher · View at Google Scholar
  28. M. Murtaza, S.-J. Dawson, D. W. Y. Tsui et al., “Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA,” Nature, vol. 497, no. 7447, pp. 108–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Uzun, Z. Akkaya, E. Dusunceli Atman et al., “Diagnostic accuracy and safety of CT-guided fine needle aspiration biopsy of pulmonary lesions with non-coaxial technique: a single center experience with 442 biopsies,” Diagnostic and Interventional Radiology, vol. 23, no. 2, pp. 137–143, 2017. View at Publisher · View at Google Scholar
  30. Y. Wang, F. Jiang, X. Tan, and P. Tian, “CT-guided percutaneous transthoracic needle biopsy for paramediastinal and nonparamediastinal lung lesions: diagnostic yield and complications in 1484 patients,” Medicine, vol. 95, no. 31, Article ID e4460, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. C. B. Laursen, T. M. H. Naur, U. Bodtger et al., “Ultrasound-guided lung biopsy in the hands of respiratory physicians: diagnostic yield and complications in 215 consecutive patients in 3 centers,” Journal of Bronchology and Interventional Pulmonology, vol. 23, no. 3, pp. 220–228, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. Overman, J. Modak, S. Kopetz et al., “Use of research biopsies in clinical trials: are risks and benefits adequately discussed?” Journal of Clinical Oncology, vol. 31, no. 1, pp. 17–22, 2013. View at Google Scholar
  33. W. Sun, X. Yuan, Y. Tian et al., “Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer,” Journal of Hematology & Oncology, vol. 8, article 95, 2015. View at Google Scholar
  34. W. Sun, X. Yuan, Y. Tian et al., “Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer,” Journal of Hematology and Oncology, vol. 8, no. 1, article 95, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. A. G. Sacher, C. Paweletz, S. E. Dahlberg et al., “Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer,” JAMA Oncology, vol. 2, no. 8, article 1014, 2016. View at Publisher · View at Google Scholar
  36. J. Sherwood, S. Dearden, M. Ratcliffe, and J. Walker, “Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review,” Journal of Experimental and Clinical Cancer Research, vol. 34, article 92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Brastianos, S. Carter, S. Santagata et al., “2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets,” European Journal of Cancer, vol. 51, supplement 3, p. S586, 2015. View at Publisher · View at Google Scholar
  38. C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Science Translational Medicine, vol. 6, Article ID 224ra24, 2014. View at Google Scholar
  39. C. L. Weston, M. J. Glantz, and J. R. Connor, “Detection of cancer cells in the cerebrospinal fluid: current methods and future directions,” Fluids and Barriers of the CNS, vol. 8, no. 1, article 14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Kawamura, A. Hata, J. Takeshita et al., “High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs,” Cancer Chemotherapy and Pharmacology, vol. 75, no. 6, pp. 1261–1266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Grommes, G. R. Oxnard, M. G. Kris et al., “Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer,” Neuro-Oncology, vol. 13, no. 12, pp. 1364–1369, 2011. View at Publisher · View at Google Scholar · View at Scopus